Martin de Haan

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index488citations26works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(6), Genetic Neurodegenerative Diseases(4), CRISPR and Genetic Engineering(3), Neurotransmitter Receptor Influence on Behavior(2), Neuroscience and Neuropharmacology Research(2)

Publications26 total

Safety, tolerability and toxicokinetics of the novel mitochondrial drug SUL-138 administered orally to rat and minipig
Toxicology Reports·2024· 1 citedOpen Access
Cisterna Magna Administration: A Robust Alternative Non-Systemic Route of Delivery for New Drug Entities in Non-Human Primates
Toxicology Letters·2021
AAV5-based gene therapy targeting ANGPTL3 reduces hyperlipidemia and development of atherosclerosis in APOE*3-Leiden.CETP mice
Atherosclerosis·2021· 1 cited
Adverse Events and Unsuccessful Intubation Attempts Are Frequent During Neonatal Nasotracheal Intubations
Frontiers in Pediatrics·2021· 25 citedOpen Access
Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system
Brain Communications·2021· 6 citedOpen Access
Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology
Brain Sciences·2021· 46 citedOpen Access
Translation of AMT-130 Preclinical Data to Inform the Design of the First FDA-approved Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest Huntington’s Disease (4531)
Neurology·2020· 8 cited
Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs
Molecular Therapy — Methods & Clinical Development·2019· 33 citedOpen Access
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs
Molecular Therapy — Methods & Clinical Development·2019· 120 citedOpen Access
The Biodistribution and Tolerability of rAAV5-miHTT after Bilateral Intra-striatal Delivery to Non-human Primates (S16.006)
Neurology·2019· 1 cited
THU-363-Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression
Journal of Hepatology·2019
Voedselweb en productiviteit van het Markermeer.
Data Archiving and Networked Services (DANS)·2019· 1 cited
AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models
Molecular Therapy — Methods & Clinical Development·2019· 85 citedOpen Access
Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system
Gene Therapy·2018· 51 citedOpen Access
Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates
Blood·2017
L4 Sustained and strong HTT silencing by AAV5-miHTT as therapy for huntington’s disease
Journal of Neurology Neurosurgery & Psychiatry·2016
The selective 5-HT 6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment
Neurobiology of Learning and Memory·2016· 22 cited
When ‘Must’ Means ‘Maybe’
2015
When ‘Must’ Means ‘Maybe’: Varieties of Risk Regulation and the Problem of Trade-offs in Europe. HowSAFE Working Paper, No. 1
2015· 5 cited
In Search of a Good First Line
In other words·2014
page 1 of 2Next →

Frequent Co-authors

Harald Petry(8), Melvin M. Evers(7), Pavlina Konstantinova(5), Bart Nijmeijer(4), S J van Deventer(4), Elisabeth A Spronck(4), Lisa Spronck(3), Valérie Ferreira(3), Astrid Vallès(3), Erich Ehlert(3), Jacek Lubelski(3), Sander van Deventer(3), Anna Majowicz(2), Margit H. Lampen(2), Cynthia Brouwers(2), Natasja de Bruin(2), Jos Prickaerts(2), Jos H.M. Lange(2), Emile Andriambeloson(2), M. van Drimmelen(2)